Research involving this compound is primarily conducted in controlled laboratory, animal, and early-phase human studies to evaluate its mechanisms of action, safety profile, and potential therapeutic applications
It is not indicated for type 1 diabetes or diabetic ketoacidosis
Back Carlsson, LMS, Carlsson, B, Jacobson, P, et al (12 July 2023) 'Life expectancy after bariatric surgery or usual care in patients with or without baseline type 2 diabetes in Swedish obese subjects', International Journal of Obesity (London) , 47/10
Microdosing flips this protocol upside down
Analysts believe the NAION risk is unlikely to significantly affect prescriptions unless Ozempic is proven unique among GLP-1 drugs in harboring this risk
Should You Be Concerned